ID   PLCE1_HUMAN             Reviewed;        2302 AA.
AC   Q9P212; A6NGW0; A6NLA1; A7MBN7; A8K1D7; B9EIJ6; Q1X6H8; Q5VWL4;
AC   Q5VWL5; Q9H9X8; Q9HBX6; Q9HC53; Q9UHV3;
DT   31-OCT-2006, integrated into UniProtKB/Swiss-Prot.
DT   31-OCT-2006, sequence version 3.
DT   10-MAY-2017, entry version 152.
DE   RecName: Full=1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase epsilon-1;
DE            EC=3.1.4.11;
DE   AltName: Full=Pancreas-enriched phospholipase C;
DE   AltName: Full=Phosphoinositide phospholipase C-epsilon-1;
DE   AltName: Full=Phospholipase C-epsilon-1;
DE            Short=PLC-epsilon-1;
GN   Name=PLCE1; Synonyms=KIAA1516, PLCE, PPLC;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, CATALYTIC
RP   ACTIVITY, COFACTOR, INTERACTION WITH HRAS AND RAP1A, SUBCELLULAR
RP   LOCATION, ENZYME REGULATION, AND VARIANTS ILE-1777 AND ARG-1927.
RC   TISSUE=Fetal brain;
RX   PubMed=11022048; DOI=10.1074/jbc.M008324200;
RA   Song C., Hu C.-D., Masago M., Kariya K., Yamawaki-Kataoka Y.,
RA   Shibatohge M., Wu D., Satoh T., Kataoka T.;
RT   "Regulation of a novel human phospholipase C, PLCepsilon, through
RT   membrane targeting by Ras.";
RL   J. Biol. Chem. 276:2752-2757(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION, TISSUE SPECIFICITY,
RP   SUBCELLULAR LOCATION, CATALYTIC ACTIVITY, ENZYME REGULATION, AND
RP   MUTAGENESIS OF HIS-1452.
RC   TISSUE=Heart;
RX   PubMed=11022047; DOI=10.1074/jbc.M008119200;
RA   Lopez I., Mak E.C., Ding J., Hamm H.E., Lomasney J.W.;
RT   "A novel bifunctional phospholipase C that is regulated by Galpha 12
RT   and stimulates the Ras/mitogen-activated protein kinase pathway.";
RL   J. Biol. Chem. 276:2758-2765(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   ARG-1927.
RC   TISSUE=Brain;
RX   PubMed=10819331; DOI=10.1093/dnares/7.2.143;
RA   Nagase T., Kikuno R., Ishikawa K., Hirosawa M., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XVII.
RT   The complete sequences of 100 new cDNA clones from brain which code
RT   for large proteins in vitro.";
RL   DNA Res. 7:143-150(2000).
RN   [4]
RP   SEQUENCE REVISION.
RA   Ohara O., Nagase T., Kikuno R.;
RL   Submitted (AUG-2003) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Cahill P., Camire D.,
RA   Carter N.P., Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Corby N., Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L.,
RA   Frankish A., Frankland J.A., Garner P., Garnett J., Gribble S.,
RA   Griffiths C., Grocock R., Gustafson E., Hammond S., Harley J.L.,
RA   Hart E., Heath P.D., Ho T.P., Hopkins B., Horne J., Howden P.J.,
RA   Huckle E., Hynds C., Johnson C., Johnson D., Kana A., Kay M.,
RA   Kimberley A.M., Kershaw J.K., Kokkinaki M., Laird G.K., Lawlor S.,
RA   Lee H.M., Leongamornlert D.A., Laird G., Lloyd C., Lloyd D.M.,
RA   Loveland J., Lovell J., McLaren S., McLay K.E., McMurray A.,
RA   Mashreghi-Mohammadi M., Matthews L., Milne S., Nickerson T.,
RA   Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V., Peck A.I.,
RA   Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A., Ross M.T.,
RA   Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W.,
RA   Tracey A., Tromans A., Tsolas J., Wall M., Walsh J., Wang H.,
RA   Weinstock K., West A.P., Willey D.L., Whitehead S.L., Wilming L.,
RA   Wray P.W., Young L., Chen Y., Lovering R.C., Moschonas N.K.,
RA   Siebert R., Fechtel K., Bentley D., Durbin R.M., Hubbard T.,
RA   Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   ARG-1927.
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1098-2302 (ISOFORMS 1/2), AND VARIANTS
RP   ILE-1777 AND ARG-1927.
RC   TISSUE=Pancreas;
RA   Kawasaki H., Chen E.J., Springett G.M., Graybiel A.M., Housman D.E.;
RT   "A novel phospholipase C enriched in pancreas.";
RL   Submitted (JAN-1999) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-1383 (ISOFORM 2), AND
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1475-2302 (ISOFORMS 1/2).
RC   TISSUE=Brain, and Teratocarcinoma;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1987-2302 (ISOFORMS 1/2).
RC   TISSUE=Brain;
RA   Buessow K.;
RT   "Sequence of cDNA clone MPMGp800D13530.";
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=11395506; DOI=10.1074/jbc.M103530200;
RA   Jin T.-G., Satoh T., Liao Y., Song C., Gao X., Kariya K., Hu C.-D.,
RA   Kataoka T.;
RT   "Role of the CDC25 homology domain of phospholipase Cepsilon in
RT   amplification of Rap1-dependent signaling.";
RL   J. Biol. Chem. 276:30301-30307(2001).
RN   [12]
RP   FUNCTION, AND ENZYME REGULATION.
RX   PubMed=11715024; DOI=10.1038/ncb1101-1020;
RA   Schmidt M., Evellin S., Weernink P.A.O., von Dorp F., Rehmann H.,
RA   Lomasney J.W., Jakobs K.H.;
RT   "A new phospholipase-C-calcium signalling pathway mediated by cyclic
RT   AMP and a Rap GTPase.";
RL   Nat. Cell Biol. 3:1020-1024(2001).
RN   [13]
RP   FUNCTION, AND ENZYME REGULATION.
RX   PubMed=11877431; DOI=10.1074/jbc.M112024200;
RA   Evellin S., Nolte J., Tysack K., vom Dorp F., Thiel M.,
RA   Weernink P.A.O., Jakobs K.H., Webb E.J., Lomasney J.W., Schmidt M.;
RT   "Stimulation of phospholipase C-epsilon by the M3 muscarinic
RT   acetylcholine receptor mediated by cyclic AMP and the GTPase Rap2B.";
RL   J. Biol. Chem. 277:16805-16813(2002).
RN   [14]
RP   INTERACTION WITH RAP1A; RAP2A AND RAP2B.
RX   PubMed=12444546; DOI=10.1038/sj.onc.1206003;
RA   Song C., Satoh T., Edamatsu H., Wu D., Tadano M., Gao X., Kataoka T.;
RT   "Differential roles of Ras and Rap1 in growth factor-dependent
RT   activation of phospholipase C epsilon.";
RL   Oncogene 21:8105-8113(2002).
RN   [15]
RP   FUNCTION.
RX   PubMed=12721365; DOI=10.1073/pnas.1031494100;
RA   Czyzyk J., Brogdon J.L., Badou A., Henegariu O., Preston Hurlburt P.,
RA   Flavell R., Bottomly K.;
RT   "Activation of CD4 T cells by Raf-independent effectors of Ras.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:6003-6008(2003).
RN   [16]
RP   ENZYME REGULATION.
RX   PubMed=15157671; DOI=10.1016/j.cellsig.2004.01.009;
RA   vom Dorp F., Sari A.Y., Sanders H., Keiper M., Oude Weernink P.A.,
RA   Jakobs K.H., Schmidt M.;
RT   "Inhibition of phospholipase C-epsilon by Gi-coupled receptors.";
RL   Cell. Signal. 16:921-928(2004).
RN   [17]
RP   INDUCTION.
RX   PubMed=16293787; DOI=10.1161/01.RES.0000196578.15385.bb;
RA   Wang H., Oestreich E.A., Maekawa N., Bullard T.A., Vikstrom K.L.,
RA   Dirksen R.T., Kelley G.G., Blaxall B.C., Smrcka A.V.;
RT   "Phospholipase C epsilon modulates beta-adrenergic receptor-dependent
RT   cardiac contraction and inhibits cardiac hypertrophy.";
RL   Circ. Res. 97:1305-1313(2005).
RN   [18]
RP   TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION.
RX   PubMed=15558028; DOI=10.1038/sj.onc.1208168;
RA   Sorli S.C., Bunney T.D., Sugden P.H., Paterson H.F., Katan M.;
RT   "Signaling properties and expression in normal and tumor tissues of
RT   two phospholipase C epsilon splice variants.";
RL   Oncogene 24:90-100(2005).
RN   [19]
RP   FUNCTION, INTERACTION WITH RRAS, AND ENZYME REGULATION.
RX   PubMed=16537651; DOI=10.1242/jcs.02835;
RA   Ada-Nguema A.S., Xenias H., Sheetz M.P., Keely P.J.;
RT   "The small GTPase R-Ras regulates organization of actin and drives
RT   membrane protrusions through the activity of PLCepsilon.";
RL   J. Cell Sci. 119:1307-1319(2006).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 2131-2246 OF MUTANT LEU-2176
RP   IN COMPLEX WITH HRAS, STRUCTURE BY NMR OF 2006-2114 AND 2131-2246, AND
RP   MUTAGENESIS OF GLN-2140; GLN-2148; ARG-2150; LYS-2171 AND TYR-2174.
RX   PubMed=16483931; DOI=10.1016/j.molcel.2006.01.008;
RA   Bunney T.D., Harris R., Gandarillas N.L., Josephs M.B., Roe S.M.,
RA   Sorli S.C., Paterson H.F., Rodrigues-Lima F., Esposito D.,
RA   Ponting C.P., Gierschik P., Pearl L.H., Driscoll P.C., Katan M.;
RT   "Structural and mechanistic insights into ras association domains of
RT   phospholipase C epsilon.";
RL   Mol. Cell 21:495-507(2006).
RN   [21]
RP   VARIANT NPHS3 LEU-1484, FUNCTION, AND INTERACTION WITH IQGAP1.
RX   PubMed=17086182; DOI=10.1038/ng1918;
RA   Hinkes B., Wiggins R.C., Gbadegesin R., Vlangos C.N., Seelow D.,
RA   Nuernberg G., Garg P., Verma R., Chaib H., Hoskins B.E., Ashraf S.,
RA   Becker C., Hennies H.C., Goyal M., Wharram B.L., Schachter A.D.,
RA   Mudumana S., Drummond I., Kerjaschki D., Waldherr R., Dietrich A.,
RA   Ozaltin F., Bakkaloglu A., Cleper R., Basel-Vanagaite L., Pohl M.,
RA   Griebel M., Tsygin A.N., Soylu A., Mueller D., Sorli C.S.,
RA   Bunney T.D., Katan M., Liu J., Attanasio M., O'toole J.F.,
RA   Hasselbacher K., Mucha B., Otto E.A., Airik R., Kispert A.,
RA   Kelley G.G., Smrcka A.V., Gudermann T., Holzman L.B., Nuernberg P.,
RA   Hildebrandt F.;
RT   "Positional cloning uncovers mutations in PLCE1 responsible for a
RT   nephrotic syndrome variant that may be reversible.";
RL   Nat. Genet. 38:1397-1405(2006).
CC   -!- FUNCTION: The production of the second messenger molecules
CC       diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) is
CC       mediated by activated phosphatidylinositol-specific phospholipase
CC       C enzymes. PLCE1 is a bifunctional enzyme which also regulates
CC       small GTPases of the Ras superfamily through its Ras guanine-
CC       exchange factor (RasGEF) activity. As an effector of
CC       heterotrimeric and small G-protein, it may play a role in cell
CC       survival, cell growth, actin organization and T-cell activation.
CC       {ECO:0000269|PubMed:11022047, ECO:0000269|PubMed:11395506,
CC       ECO:0000269|PubMed:11715024, ECO:0000269|PubMed:11877431,
CC       ECO:0000269|PubMed:12721365, ECO:0000269|PubMed:16537651,
CC       ECO:0000269|PubMed:17086182}.
CC   -!- CATALYTIC ACTIVITY: 1-phosphatidyl-1D-myo-inositol 4,5-
CC       bisphosphate + H(2)O = 1D-myo-inositol 1,4,5-trisphosphate +
CC       diacylglycerol. {ECO:0000269|PubMed:11022047,
CC       ECO:0000269|PubMed:11022048}.
CC   -!- COFACTOR:
CC       Name=Ca(2+); Xref=ChEBI:CHEBI:29108;
CC         Evidence={ECO:0000269|PubMed:11022048};
CC   -!- ENZYME REGULATION: Activated by the heterotrimeric G-protein
CC       subunits GNA12, GNA13 and GNB1-GNG2. Activated by HRAS, RAP1A,
CC       RHOA, RHOB, RHOC, RRAS and RRAS2. Activated by the G(s)-coupled
CC       GPCRs ADRB2, PTGER1 and CHRM3 through cyclic-AMP formation and
CC       RAP2B activation. Inhibited by G(i)-coupled GPCRs.
CC       {ECO:0000269|PubMed:11022047, ECO:0000269|PubMed:11022048,
CC       ECO:0000269|PubMed:11715024, ECO:0000269|PubMed:11877431,
CC       ECO:0000269|PubMed:15157671, ECO:0000269|PubMed:16537651}.
CC   -!- SUBUNIT: Interacts with RHOA (By similarity). Interacts with
CC       IQGAP1, HRAS, RAP1A, RAP2A, RAP2B and RRAS. {ECO:0000250,
CC       ECO:0000269|PubMed:11022048, ECO:0000269|PubMed:12444546,
CC       ECO:0000269|PubMed:16483931, ECO:0000269|PubMed:16537651,
CC       ECO:0000269|PubMed:17086182}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytosol. Cell membrane. Golgi
CC       apparatus membrane. Note=Recruited to plasma membrane by activated
CC       HRAS and RAP2. Recruited to perinuclear membrane by activated
CC       RAP1A. Isoform 1 and isoform 2 associates with Golgi membranes.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=PLCepsilon1a;
CC         IsoId=Q9P212-1; Sequence=Displayed;
CC       Name=2; Synonyms=PLCepsilon1b;
CC         IsoId=Q9P212-2; Sequence=VSP_021335, VSP_021336;
CC         Note=Ref.2 (AAG28341) sequence is in conflict in position:
CC         69:L->P. {ECO:0000305};
CC   -!- TISSUE SPECIFICITY: Widely expressed. Isoform 1 is broadly
CC       expressed and only absent in peripheral blood leukocytes. Isoform
CC       2 is specifically expressed in placenta, lung and spleen.
CC       {ECO:0000269|PubMed:11022047, ECO:0000269|PubMed:11022048,
CC       ECO:0000269|PubMed:15558028}.
CC   -!- INDUCTION: Overexpressed during heart failure.
CC       {ECO:0000269|PubMed:16293787}.
CC   -!- DOMAIN: The Ras-associating domain 1 is degenerated and may not
CC       bind HRAS. The Ras-associating domain 2 mediates interaction with
CC       GTP-bound HRAS, RAP1A, RAP2A and RAP2B and recruitment of HRAS to
CC       the cell membrane.
CC   -!- DOMAIN: The Ras-GEF domain has a GEF activity towards HRAS and
CC       RAP1A. Mediates activation of the mitogen-activated protein kinase
CC       pathway.
CC   -!- DISEASE: Nephrotic syndrome 3 (NPHS3) [MIM:610725]: A form of
CC       nephrotic syndrome, a renal disease clinically characterized by
CC       severe proteinuria, resulting in complications such as
CC       hypoalbuminemia, hyperlipidemia and edema. Kidney biopsies show
CC       non-specific histologic changes such as focal segmental
CC       glomerulosclerosis and diffuse mesangial proliferation. Some
CC       affected individuals have an inherited steroid-resistant form and
CC       progress to end-stage renal failure. Most patients with NPHS3 show
CC       diffuse mesangial sclerosis on renal biopsy, which is a pathologic
CC       entity characterized by mesangial matrix expansion with no
CC       mesangial hypercellularity, hypertrophy of the podocytes,
CC       vacuolized podocytes, thickened basement membranes, and diminished
CC       patency of the capillary lumen. {ECO:0000269|PubMed:17086182}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAF22005.1; Type=Frameshift; Positions=1131; Evidence={ECO:0000305};
CC       Sequence=AAG17145.2; Type=Frameshift; Positions=2296; Evidence={ECO:0000305};
CC       Sequence=BAA96040.2; Type=Erroneous initiation; Evidence={ECO:0000305};
CC       Sequence=BAB14090.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC       Sequence=CAH70739.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC       Sequence=CAH73288.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC       Sequence=CAH73757.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC       Sequence=CAI16674.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF190642; AAG17145.2; ALT_FRAME; mRNA.
DR   EMBL; AF170071; AAG28341.1; -; mRNA.
DR   EMBL; AB040949; BAA96040.2; ALT_INIT; mRNA.
DR   EMBL; AL139118; CAH70739.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AL139124; CAH70739.1; JOINED; Genomic_DNA.
DR   EMBL; AL365510; CAH70739.1; JOINED; Genomic_DNA.
DR   EMBL; AL389885; CAH70739.1; JOINED; Genomic_DNA.
DR   EMBL; AL139118; CAH70740.1; -; Genomic_DNA.
DR   EMBL; AL139124; CAH70740.1; JOINED; Genomic_DNA.
DR   EMBL; AL365510; CAH70740.1; JOINED; Genomic_DNA.
DR   EMBL; AL389885; CAH70740.1; JOINED; Genomic_DNA.
DR   EMBL; AL389885; CAH73288.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AL139118; CAH73288.1; JOINED; Genomic_DNA.
DR   EMBL; AL139124; CAH73288.1; JOINED; Genomic_DNA.
DR   EMBL; AL365510; CAH73288.1; JOINED; Genomic_DNA.
DR   EMBL; AL389885; CAH73289.1; -; Genomic_DNA.
DR   EMBL; AL139118; CAH73289.1; JOINED; Genomic_DNA.
DR   EMBL; AL139124; CAH73289.1; JOINED; Genomic_DNA.
DR   EMBL; AL365510; CAH73289.1; JOINED; Genomic_DNA.
DR   EMBL; AL365510; CAH73757.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AL139118; CAH73757.1; JOINED; Genomic_DNA.
DR   EMBL; AL139124; CAH73757.1; JOINED; Genomic_DNA.
DR   EMBL; AL389885; CAH73757.1; JOINED; Genomic_DNA.
DR   EMBL; AL365510; CAH73758.1; -; Genomic_DNA.
DR   EMBL; AL139118; CAH73758.1; JOINED; Genomic_DNA.
DR   EMBL; AL139124; CAH73758.1; JOINED; Genomic_DNA.
DR   EMBL; AL389885; CAH73758.1; JOINED; Genomic_DNA.
DR   EMBL; AL139124; CAI16674.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AL139118; CAI16674.1; JOINED; Genomic_DNA.
DR   EMBL; AL365510; CAI16674.1; JOINED; Genomic_DNA.
DR   EMBL; AL389885; CAI16674.1; JOINED; Genomic_DNA.
DR   EMBL; AL139124; CAI16675.1; -; Genomic_DNA.
DR   EMBL; AL139118; CAI16675.1; JOINED; Genomic_DNA.
DR   EMBL; AL365510; CAI16675.1; JOINED; Genomic_DNA.
DR   EMBL; AL389885; CAI16675.1; JOINED; Genomic_DNA.
DR   EMBL; CH471066; EAW50042.1; -; Genomic_DNA.
DR   EMBL; CH471066; EAW50043.1; -; Genomic_DNA.
DR   EMBL; BC140705; AAI40706.1; -; mRNA.
DR   EMBL; BC151854; AAI51855.1; -; mRNA.
DR   EMBL; AF117948; AAF22005.1; ALT_FRAME; mRNA.
DR   EMBL; AK022543; BAB14090.1; ALT_INIT; mRNA.
DR   EMBL; AK289852; BAF82541.1; -; mRNA.
DR   EMBL; AY995135; AAY45890.1; -; mRNA.
DR   CCDS; CCDS41552.1; -. [Q9P212-1]
DR   CCDS; CCDS53555.1; -. [Q9P212-2]
DR   RefSeq; NP_001159451.1; NM_001165979.2. [Q9P212-2]
DR   RefSeq; NP_001275918.1; NM_001288989.1.
DR   RefSeq; NP_057425.3; NM_016341.3. [Q9P212-1]
DR   UniGene; Hs.655033; -.
DR   PDB; 2BYE; NMR; -; A=2006-2114.
DR   PDB; 2BYF; NMR; -; A=2131-2246.
DR   PDB; 2C5L; X-ray; 1.90 A; C/D=2131-2246.
DR   PDBsum; 2BYE; -.
DR   PDBsum; 2BYF; -.
DR   PDBsum; 2C5L; -.
DR   ProteinModelPortal; Q9P212; -.
DR   SMR; Q9P212; -.
DR   BioGrid; 119370; 5.
DR   IntAct; Q9P212; 3.
DR   MINT; MINT-1420367; -.
DR   STRING; 9606.ENSP00000260766; -.
DR   SwissLipids; SLP:000000663; -.
DR   iPTMnet; Q9P212; -.
DR   PhosphoSitePlus; Q9P212; -.
DR   BioMuta; PLCE1; -.
DR   DMDM; 118595723; -.
DR   PaxDb; Q9P212; -.
DR   PeptideAtlas; Q9P212; -.
DR   PRIDE; Q9P212; -.
DR   Ensembl; ENST00000371375; ENSP00000360426; ENSG00000138193. [Q9P212-2]
DR   Ensembl; ENST00000371380; ENSP00000360431; ENSG00000138193. [Q9P212-1]
DR   Ensembl; ENST00000371385; ENSP00000360438; ENSG00000138193. [Q9P212-2]
DR   GeneID; 51196; -.
DR   KEGG; hsa:51196; -.
DR   UCSC; uc001kjk.4; human. [Q9P212-1]
DR   CTD; 51196; -.
DR   DisGeNET; 51196; -.
DR   GeneCards; PLCE1; -.
DR   H-InvDB; HIX0009051; -.
DR   H-InvDB; HIX0035415; -.
DR   HGNC; HGNC:17175; PLCE1.
DR   HPA; HPA015597; -.
DR   HPA; HPA015598; -.
DR   MalaCards; PLCE1; -.
DR   MIM; 608414; gene.
DR   MIM; 610725; phenotype.
DR   neXtProt; NX_Q9P212; -.
DR   OpenTargets; ENSG00000138193; -.
DR   Orphanet; 93217; Familial idiopathic steroid-resistant nephrotic syndrome with diffuse mesangial sclerosis.
DR   Orphanet; 93213; Familial idiopathic steroid-resistant nephrotic syndrome with focal segmental hyalinosis.
DR   PharmGKB; PA33391; -.
DR   eggNOG; KOG0169; Eukaryota.
DR   eggNOG; ENOG410XPSW; LUCA.
DR   GeneTree; ENSGT00730000110782; -.
DR   HOVERGEN; HBG059220; -.
DR   InParanoid; Q9P212; -.
DR   KO; K05860; -.
DR   OMA; QHTACQL; -.
DR   OrthoDB; EOG091G03PC; -.
DR   PhylomeDB; Q9P212; -.
DR   TreeFam; TF314432; -.
DR   BioCyc; MetaCyc:HS06473-MONOMER; -.
DR   BRENDA; 3.1.4.11; 2681.
DR   Reactome; R-HSA-1855204; Synthesis of IP3 and IP4 in the cytosol.
DR   SIGNOR; Q9P212; -.
DR   ChiTaRS; PLCE1; human.
DR   EvolutionaryTrace; Q9P212; -.
DR   GeneWiki; PLCE1; -.
DR   GenomeRNAi; 51196; -.
DR   PRO; PR:Q9P212; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   Bgee; ENSG00000138193; -.
DR   Genevisible; Q9P212; HS.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0000139; C:Golgi membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0005085; F:guanyl-nucleotide exchange factor activity; TAS:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004435; F:phosphatidylinositol phospholipase C activity; IDA:UniProtKB.
DR   GO; GO:0004629; F:phospholipase C activity; IDA:UniProtKB.
DR   GO; GO:0017016; F:Ras GTPase binding; TAS:UniProtKB.
DR   GO; GO:0005057; F:signal transducer activity, downstream of receptor; TAS:UniProtKB.
DR   GO; GO:0000187; P:activation of MAPK activity; IDA:UniProtKB.
DR   GO; GO:0019722; P:calcium-mediated signaling; TAS:UniProtKB.
DR   GO; GO:0008283; P:cell proliferation; NAS:UniProtKB.
DR   GO; GO:0007010; P:cytoskeleton organization; NAS:UniProtKB.
DR   GO; GO:0006651; P:diacylglycerol biosynthetic process; TAS:UniProtKB.
DR   GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; NAS:UniProtKB.
DR   GO; GO:0032835; P:glomerulus development; IMP:HGNC.
DR   GO; GO:0007507; P:heart development; TAS:UniProtKB.
DR   GO; GO:0043647; P:inositol phosphate metabolic process; TAS:Reactome.
DR   GO; GO:0048016; P:inositol phosphate-mediated signaling; TAS:UniProtKB.
DR   GO; GO:0016042; P:lipid catabolic process; IEA:UniProtKB-KW.
DR   GO; GO:0007200; P:phospholipase C-activating G-protein coupled receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0006644; P:phospholipid metabolic process; IC:UniProtKB.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; TAS:UniProtKB.
DR   GO; GO:0007205; P:protein kinase C-activating G-protein coupled receptor signaling pathway; NAS:UniProtKB.
DR   GO; GO:0007265; P:Ras protein signal transduction; TAS:UniProtKB.
DR   GO; GO:0001558; P:regulation of cell growth; TAS:UniProtKB.
DR   GO; GO:0008277; P:regulation of G-protein coupled receptor protein signaling pathway; IDA:UniProtKB.
DR   GO; GO:0045859; P:regulation of protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0046578; P:regulation of Ras protein signal transduction; IDA:UniProtKB.
DR   GO; GO:0006940; P:regulation of smooth muscle contraction; TAS:UniProtKB.
DR   Gene3D; 1.10.840.10; -; 1.
DR   Gene3D; 2.60.40.150; -; 1.
DR   Gene3D; 3.20.20.190; -; 1.
DR   InterPro; IPR000008; C2_dom.
DR   InterPro; IPR011992; EF-hand-dom_pair.
DR   InterPro; IPR001192; PI-PLC_fam.
DR   InterPro; IPR028398; PLC-epsilon1.
DR   InterPro; IPR017946; PLC-like_Pdiesterase_TIM-brl.
DR   InterPro; IPR015359; PLC_EF-hand-like.
DR   InterPro; IPR000909; PLipase_C_PInositol-sp_X_dom.
DR   InterPro; IPR001711; PLipase_C_Pinositol-sp_Y.
DR   InterPro; IPR000159; RA_dom.
DR   InterPro; IPR023578; Ras_GEF_dom.
DR   InterPro; IPR001895; RASGEF_cat_dom.
DR   InterPro; IPR029071; Ubiquitin-rel_dom.
DR   PANTHER; PTHR10336; PTHR10336; 1.
DR   PANTHER; PTHR10336:SF111; PTHR10336:SF111; 1.
DR   Pfam; PF00168; C2; 1.
DR   Pfam; PF09279; EF-hand_like; 1.
DR   Pfam; PF00388; PI-PLC-X; 1.
DR   Pfam; PF00387; PI-PLC-Y; 1.
DR   Pfam; PF00788; RA; 1.
DR   Pfam; PF00617; RasGEF; 1.
DR   PRINTS; PR00390; PHPHLIPASEC.
DR   SMART; SM00239; C2; 1.
DR   SMART; SM00148; PLCXc; 1.
DR   SMART; SM00149; PLCYc; 1.
DR   SMART; SM00314; RA; 1.
DR   SMART; SM00147; RasGEF; 1.
DR   SUPFAM; SSF47473; SSF47473; 2.
DR   SUPFAM; SSF48366; SSF48366; 3.
DR   SUPFAM; SSF49562; SSF49562; 1.
DR   SUPFAM; SSF51695; SSF51695; 3.
DR   SUPFAM; SSF54236; SSF54236; 2.
DR   PROSITE; PS50004; C2; 1.
DR   PROSITE; PS50007; PIPLC_X_DOMAIN; 1.
DR   PROSITE; PS50008; PIPLC_Y_DOMAIN; 1.
DR   PROSITE; PS50200; RA; 1.
DR   PROSITE; PS50009; RASGEF_CAT; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Calcium; Cell membrane;
KW   Complete proteome; Cytoplasm; Disease mutation; Golgi apparatus;
KW   Guanine-nucleotide releasing factor; Hydrolase; Lipid degradation;
KW   Lipid metabolism; Membrane; Metal-binding; Phosphoprotein;
KW   Polymorphism; Reference proteome; Repeat; Transducer.
FT   CHAIN         1   2302       1-phosphatidylinositol 4,5-bisphosphate
FT                                phosphodiesterase epsilon-1.
FT                                /FTId=PRO_0000256238.
FT   DOMAIN      531    790       Ras-GEF. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00168}.
FT   DOMAIN     1392   1540       PI-PLC X-box. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00270}.
FT   DOMAIN     1730   1846       PI-PLC Y-box. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00271}.
FT   DOMAIN     1856   1956       C2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00041}.
FT   DOMAIN     2012   2114       Ras-associating 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00166}.
FT   DOMAIN     2135   2238       Ras-associating 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00166}.
FT   REGION     1686   1764       Required for activation by RHOA, RHOB,
FT                                GNA12, GNA13 and G-beta gamma.
FT                                {ECO:0000250}.
FT   ACT_SITE   1407   1407       {ECO:0000255|PROSITE-ProRule:PRU00270}.
FT   ACT_SITE   1452   1452       {ECO:0000255|PROSITE-ProRule:PRU00270}.
FT   MOD_RES    1096   1096       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q8K4S1}.
FT   VAR_SEQ       1    308       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:11022047,
FT                                ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_021335.
FT   VAR_SEQ     309    402       DVEEDAFKSKKERSTLLVRRFCKNDREVKKSVYTGTRAIVR
FT                                TLPSGHIGLTAWSYIDQKRNGPLLPCGRVMEPPSTVEIRQD
FT                                GSQRLSEAQWYP -> MVSEGSAAGRDFAGMEEVRQLHVRF
FT                                CKGIKIWHQAWFLCSLLGREPQEREAGCQLWLCTLSAVLKV
FT                                GWLFPLSEVPNFTLLKDGCGCWRLKEDQ (in isoform
FT                                2). {ECO:0000303|PubMed:11022047,
FT                                ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_021336.
FT   VARIANT     469    469       S -> T (in dbSNP:rs17508082).
FT                                /FTId=VAR_031843.
FT   VARIANT     548    548       R -> L (in dbSNP:rs17417407).
FT                                /FTId=VAR_031844.
FT   VARIANT    1484   1484       S -> L (in NPHS3; gives rise to focal
FT                                segmental glomerulosclerosis rather than
FT                                diffuse mesangial sclerosis;
FT                                dbSNP:rs121912605).
FT                                {ECO:0000269|PubMed:17086182}.
FT                                /FTId=VAR_029883.
FT   VARIANT    1575   1575       R -> P (in dbSNP:rs2274224).
FT                                /FTId=VAR_031845.
FT   VARIANT    1777   1777       T -> I (in dbSNP:rs3765524).
FT                                {ECO:0000269|PubMed:11022048,
FT                                ECO:0000269|Ref.8}.
FT                                /FTId=VAR_031846.
FT   VARIANT    1927   1927       H -> R (in dbSNP:rs2274223).
FT                                {ECO:0000269|PubMed:10819331,
FT                                ECO:0000269|PubMed:11022048,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|Ref.8}.
FT                                /FTId=VAR_031847.
FT   MUTAGEN    1452   1452       H->L: Loss of the phospholipase C
FT                                enzymatic activity. Still activates HRAS
FT                                and the MAP kinase pathway.
FT                                {ECO:0000269|PubMed:11022047}.
FT   MUTAGEN    2140   2140       Q->E: Increases 2.8-fold the affinity for
FT                                HRAS. {ECO:0000269|PubMed:16483931}.
FT   MUTAGEN    2148   2148       Q->E: Decreases 17.5-fold the affinity
FT                                for HRAS. {ECO:0000269|PubMed:16483931}.
FT   MUTAGEN    2148   2148       Q->K: Increases 1.4-fold the affinity for
FT                                HRAS. {ECO:0000269|PubMed:16483931}.
FT   MUTAGEN    2150   2150       R->L: Abolishes interaction with HRAS.
FT                                {ECO:0000269|PubMed:16483931}.
FT   MUTAGEN    2171   2171       K->L: No effect on HRAS-binding.
FT                                {ECO:0000269|PubMed:16483931}.
FT   MUTAGEN    2174   2174       Y->L: Reduces HRAS-binding.
FT                                {ECO:0000269|PubMed:16483931}.
FT   CONFLICT    502    502       G -> S (in Ref. 2; AAG28341).
FT                                {ECO:0000305}.
FT   CONFLICT    703    703       V -> F (in Ref. 2; AAG28341).
FT                                {ECO:0000305}.
FT   CONFLICT   1133   1133       E -> K (in Ref. 2; AAG28341).
FT                                {ECO:0000305}.
FT   CONFLICT   1229   1230       SR -> QA (in Ref. 8; AAF22005).
FT                                {ECO:0000305}.
FT   CONFLICT   1456   1456       L -> P (in Ref. 1; AAG17145).
FT                                {ECO:0000305}.
FT   CONFLICT   1571   1571       N -> D (in Ref. 9; BAB14090).
FT                                {ECO:0000305}.
FT   CONFLICT   1575   1575       R -> Q (in Ref. 2; AAG28341).
FT                                {ECO:0000305}.
FT   CONFLICT   1672   1672       C -> R (in Ref. 1; AAG17145).
FT                                {ECO:0000305}.
FT   CONFLICT   1705   1705       P -> L (in Ref. 9; BAB14090).
FT                                {ECO:0000305}.
FT   CONFLICT   2125   2125       D -> G (in Ref. 9; BAB14090).
FT                                {ECO:0000305}.
FT   STRAND     2015   2020       {ECO:0000244|PDB:2BYE}.
FT   STRAND     2022   2031       {ECO:0000244|PDB:2BYE}.
FT   HELIX      2038   2046       {ECO:0000244|PDB:2BYE}.
FT   STRAND     2049   2052       {ECO:0000244|PDB:2BYE}.
FT   STRAND     2058   2064       {ECO:0000244|PDB:2BYE}.
FT   STRAND     2069   2072       {ECO:0000244|PDB:2BYE}.
FT   STRAND     2081   2084       {ECO:0000244|PDB:2BYE}.
FT   STRAND     2086   2088       {ECO:0000244|PDB:2BYE}.
FT   HELIX      2090   2096       {ECO:0000244|PDB:2BYE}.
FT   TURN       2099   2103       {ECO:0000244|PDB:2BYE}.
FT   STRAND     2107   2112       {ECO:0000244|PDB:2BYE}.
FT   STRAND     2136   2143       {ECO:0000244|PDB:2C5L}.
FT   STRAND     2150   2156       {ECO:0000244|PDB:2C5L}.
FT   HELIX      2161   2171       {ECO:0000244|PDB:2C5L}.
FT   TURN       2172   2174       {ECO:0000244|PDB:2C5L}.
FT   HELIX      2176   2180       {ECO:0000244|PDB:2C5L}.
FT   HELIX      2184   2186       {ECO:0000244|PDB:2C5L}.
FT   STRAND     2187   2194       {ECO:0000244|PDB:2C5L}.
FT   STRAND     2198   2204       {ECO:0000244|PDB:2BYF}.
FT   STRAND     2207   2211       {ECO:0000244|PDB:2C5L}.
FT   HELIX      2218   2223       {ECO:0000244|PDB:2C5L}.
FT   STRAND     2229   2235       {ECO:0000244|PDB:2C5L}.
FT   TURN       2236   2238       {ECO:0000244|PDB:2C5L}.
SQ   SEQUENCE   2302 AA;  258715 MW;  71DDE446277077A3 CRC64;
     MTSEEMTASV LIPVTQRKVV SAQSAADESS EKVSDINISK AHTVRRSGET SHTISQLNKL
     KEEPSGSNLP KILSIAREKI VSDENSNEKC WEKIMPDSAK NLNINCNNIL RNHQHGLPQR
     QFYEMYNSVA EEDLCLETGI PSPLERKVFP GIQLELDRPS MGISPLGNQS VIIETGRAHP
     DSRRAVFHFH YEVDRRMSDT FCTLSENLIL DDCGNCVPLP GGEEKQKKNY VAYTCKLMEL
     AKNCDNKNEQ LQCDHCDTLN DKYFCFEGSC EKVDMVYSGD SFCRKDFTDS QAAKTFLSHF
     EDFPDNCDDV EEDAFKSKKE RSTLLVRRFC KNDREVKKSV YTGTRAIVRT LPSGHIGLTA
     WSYIDQKRNG PLLPCGRVME PPSTVEIRQD GSQRLSEAQW YPIYNAVRRE ETENTVGSLL
     HFLTKLPASE TAHGRISVGP CLKQCVRDTV CEYRATLQRT SISQYITGSL LEATTSLGAR
     SGLLSTFGGS TGRMMLKERQ PGPSVANSNA LPSSSAGISK ELIDLQPLIQ FPEEVASILM
     EQEQTIYRRV LPVDYLCFLT RDLGTPECQS SLPCLKASIS ASILTTQNGE HNALEDLVMR
     FNEVSSWVTW LILTAGSMEE KREVFSYLVH VAKCCWNMGN YNAVMEFLAG LRSRKVLKMW
     QFMDQSDIET MRSLKDAMAQ HESSCEYRKV VTRALHIPGC KVVPFCGVFL KELCEVLDGA
     SGLMKLCPRY NSQEETLEFV ADYSGQDNFL QRVGQNGLKN SEKESTVNSI FQVIRSCNRS
     LETDEEDSPS EGNSSRKSSL KDKSRWQFII GDLLDSDNDI FEQSKEYDSH GSEDSQKAFD
     HGTELIPWYV LSIQADVHQF LLQGATVIHY DQDTHLSARC FLQLQPDNST LTWVKPTTAS
     PASSKAKLGV LNNTAEPGKF PLLGNAGLSS LTEGVLDLFA VKAVYMGHPG IDIHTVCVQN
     KLGSMFLSET GVTLLYGLQT TDNRLLHFVA PKHTAKMLFS GLLELTRAVR KMRKFPDQRQ
     QWLRKQYVSL YQEDGRYEGP TLAHAVELFG GRRWSARNPS PGTSAKNAEK PNMQRNNTLG
     ISTTKKKKKI LMRGESGEVT DDEMATRKAK MHKECRSRSG SDPQDINEQE ESEVNAIANP
     PNPLPSRRAH SLTTAGSPNL AAGTSSPIRP VSSPVLSSSN KSPSSAWSSS SWHGRIKGGM
     KGFQSFMVSD SNMSFVEFVE LFKSFSVRSR KDLKDLFDVY AVPCNRSGSE SAPLYTNLTI
     DENTSDLQPD LDLLTRNVSD LGLFIKSKQQ LSDNQRQISD AIAAASIVTN GTGIESTSLG
     IFGVGILQLN DFLVNCQGEH CTYDEILSII QKFEPSISMC HQGLMSFEGF ARFLMDKENF
     ASKNDESQEN IKELQLPLSY YYIESSHNTY LTGHQLKGES SVELYSQVLL QGCRSVELDC
     WDGDDGMPII YHGHTLTTKI PFKEVVEAID RSAFINSDLP IIISIENHCS LPQQRKMAEI
     FKTVFGEKLV TKFLFETDFS DDPMLPSPDQ LRKKVLLKNK KLKAHQTPVD ILKQKAHQLA
     SMQVQAYNGG NANPRPANNE EEEDEEDEYD YDYESLSDDN ILEDRPENKS CNDKLQFEYN
     EEIPKRIKKA DNSACNKGKV YDMELGEEFY LDQNKKESRQ IAPELSDLVI YCQAVKFPGL
     STLNASGSSR GKERKSRKSI FGNNPGRMSP GETASFNKTS GKSSCEGIRQ TWEESSSPLN
     PTTSLSAIIR TPKCYHISSL NENAAKRLCR RYSQKLTQHT ACQLLRTYPA ATRIDSSNPN
     PLMFWLHGIQ LVALNYQTDD LPLHLNAAMF EANGGCGYVL KPPVLWDKNC PMYQKFSPLE
     RDLDSMDPAV YSLTIVSGQN VCPSNSMGSP CIEVDVLGMP LDSCHFRTKP IHRNTLNPMW
     NEQFLFHVHF EDLVFLRFAV VENNSSAVTA QRIIPLKALK RGYRHLQLRN LHNEVLEISS
     LFINSRRMEE NSSGNTMSAS SMFNTEERKC LQTHRVTVHG VPGPEPFTVF TINGGTKAKQ
     LLQQILTNEQ DIKPVTTDYF LMEEKYFISK EKNECRKQPF QRAIGPEEEI MQILSSWFPE
     EGYMGRIVLK TQQENLEEKN IVQDDKEVIL SSEEESFFVQ VHDVSPEQPR TVIKAPRVST
     AQDVIQQTLC KAKYSYSILS NPNPSDYVLL EEVVKDTTNK KTTTPKSSQR VLLDQECVFQ
     AQSKWKGAGK FILKLKEQVQ ASREDKKKGI SFASELKKLT KSTKQPRGLT SPSQLLTSES
     IQTKEEKPVG GLSSSDTMDY RQ
//
